Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series D convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $11.3 million. ADVENTRX plans to use the net proceeds from the offering to fund its operations during the FDA review period of an ANX-530 NDA and to continue development of ANX-514, and for general corporate purposes.

The preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.18805 per share and will accrue a 4.25660% cumulative dividend until October 9, 2020. If the convertible preferred stock is converted at any time prior to October 9, 2020, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through October 9, 2020, or $468.23 per $1,000 stated value of preferred stock converted, less any dividend payments made with respect to the converted preferred stock. Approximately $5.3 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above. The investors also will receive warrants to purchase an aggregate of 19,800,000 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.1468 per share and are exercisable at any time after the closing of the transaction and before the fifth anniversary of the initial exercise date.

The convertible preferred stock and warrants were sold by ADVENTRX pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission ("SEC"). A prospectus
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... DIEGO , Oct. 20, 2014   BioNano Genomics ... Irys system: the ability to collect human data at 30X ... a single chip.  This new capability was established and demonstrated ... the Irys TM System and will be ... two months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... By Dennis Thompson HealthDay ... freelance cameraman who was diagnosed with Ebola while working for ... system and can leave the special isolation unit at Nebraska Medical ... two weeks, the hospital said Tuesday. A blood test confirmed ... Ashoka Mukpo, 33, can head home to Providence, R.I., NBC ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 7 (HealthDay News) -- Imaging scans show that chronic daily ... brain, according to a new report. In the study, ... decrease in the number of receptors involved in a wide ... coordination, pleasure, pain tolerance, memory and appetite. Marijuana, also ...
... News) -- Increasing out-of-pocket expenses forces many cancer patients ... appointments and to cut back on food and other ... at 216 cancer patients who sought help from the ... expensive medications. All but one patient had insurance, two-thirds ...
... June 7 (HealthDay News) -- People who have hip or ... are at greater risk for serious complications after the procedure, ... patients at hospitals with low surgical volume, as were deaths ... published online June 7 in Arthritis & Rheumatism . ...
... engineer will test parts of Galveston Bay for toxic ... the best way to handle those pollutants., Hanadi Rifai ... Texas Commission on Environmental Quality (TCEQ) grant that is ... for similar research in the Houston Ship Channel. The ...
... objects, sounds, smells and events: far too much for us ... automatically be snagged by something startling, such as a slamming ... important to us right then, such as locating our child ... also know that people are hard-wired to seek out and ...
... HealthDay Reporter , TUESDAY, June 7 (HealthDay News) -- ... it? A new study suggests that might be a good ... a game when they got some shut-eye afterward. The research ... it does provide more evidence that your brain doesn,t just rest ...
Cached Medicine News:Health News:Chronic Pot Smoking Affects Brain Chemistry, Scans Show 2Health News:Cancer Patients Struggle as Drug Costs Soar: Study 2Health News:Joint Replacement Risks Rise at Less Experienced Hospitals 2Health News:University of Houston researcher receives grant to study water pollutants 2Health News:Your attention please: 'Rewarding' objects can't be ignored 2Health News:Your attention please: 'Rewarding' objects can't be ignored 3Health News:Sleep Might Help You Solve Problems Better 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: